Država: Novi Zeland
Jezik: engleski
Izvor: Medsafe (Medicines Safety Authority)
Deferiprone 500mg;
Chiesi New Zealand Limited t/a Emerge Health
Deferiprone 500 mg
500 mg
Film coated tablet
Active: Deferiprone 500mg Excipient: Colloidal silicon dioxide Hypromellose Macrogol 3350 Magnesium stearate Microcrystalline cellulose Titanium dioxide
Bottle, plastic, 120 mL HDPE bottle child resistant closure with induction seal and foam liner, 100 tablets
Prescription
Prescription
Srini Pharmaceuticals Pvt Ltd
Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective.
Package - Contents - Shelf Life: Bottle, plastic, 120 mL HDPE bottle child resistant closure with induction seal and foam liner - 100 tablets - 60 months from date of manufacture stored at or below 25°C
2008-12-05
FERRIPROX 500 mg Tablets 1 FERRIPROX ® 500 MG TABLETS Contains the active ingredient deferiprone CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ferriprox. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. The information in this leaflet was last updated on the date listed on the last page. More recent information on this medicine may be available. ASK YOUR DOCTOR OR PHARMACIST: if there is anything you do not understand in this leaflet, if you are worried about taking your medicine, or to obtain the most up-to-date information. All medicines have risks and benefits. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you. IF YOU HAVE CONCERNS ABOUT TAKING FERRIPROX, ASK YOUR DOCTOR. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may want to read it again. WHAT FERRIPROX IS USED FOR Ferriprox contains the active ingredient deferiprone and is used for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine or in whom desferrioxamine therapy has proven ineffective. Ferriprox is a medicine that removes iron from the body. In a disease such as thalassaemia major, there is accumulation of iron in the body in those patients who are dependent on blood transfusions. If not removed, the iron levels can reach a serious level in the body as a result of the accumulation. By removing the excess iron from the body, Ferriprox can reduce the serious effects of iron overload. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY FERRIPROX HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed this medicine for another use. Ferriprox is not addictive. This medicine is available only with a doctor's prescription. BEFORE YOU TAKE THIS MEDICINE WHEN YOU MUST NOT TAKE IT DO NOT TAKE FERRIPROX IF YOU OR YOUR CHILD: have a history of hypersensitivity (an allergy) to deferiprone or any of the Pročitajte cijeli dokument
FERRIPROX Data Sheet v2.1 1 NEW ZEALAND DATA SHEET FERRIPROX DEFERIPRONE 500 MG TABLET DEFERIPRONE 1000 MG TABLET DEFERIPRONE 100 MG/ML ORAL SOLUTION 1. PRODUCT NAME Ferriprox ® 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Deferiprone 500 mg film-coated tablets Deferiprone 1000 mg film-coated tablets Deferiprone 100 mg/mL oral solution Excipient(s) of known effect Ferriprox tablets and Ferriprox oral solution are lactose and gluten free. Ferriprox oral solution contains sucralose and the colorant sunset yellow FCF. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM 500 mg film-coated tablets Ferriprox 500 mg tablets are white to off white, capsule-shaped, film-coated, scored and imprinted “APO” bisect “500” on one side, plain on the other side. The tablets are breakable in half. 1000 mg film-coated tablets Ferriprox 1000 mg tablets are white to off white, capsule-shaped, film-coated, scored and imprinted "APO" bisect "1000" on one side, plain on the other side. The tablets are breakable in half. 100 mg/mL oral solution Ferriprox oral solution is a clear, reddish orange solution with a peppermint and cherry- flavoured aroma. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective. 4.2 DOSE AND METHOD OF ADMINISTRATION Therapy with Ferriprox should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia. FERRIPROX Data Sheet v2.1 2 Ferriprox is given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. The dose was not developed through a formal dose finding study, but rather through literature evaluation and assessment of an effective dose to produce iron excretion equivalent to the transfusional input. Dosage per kilogram body weight should be calculated to the nearest half tablet or to the nearest 2.5 m Pročitajte cijeli dokument